GILD

Gilead Sciencesの空売り状況は、投資家がGilead Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Gilead Sciences (NASDAQ:GILD) 株価情報, 空売り情報

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

GILEAD SCIENCES ORD

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $95 to $105.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $105

Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41786284/gilead-sciences-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">fiscal year 2024 guidance</a>.
On Wednesday after market, Gilead reported third-quarter adjusted EPS of $2.02, down from $2.29 a year ago, beating the consensus of $1.55.
The HIV drug maker reported sales of $7.55 billion, up 7% year over year, beating the consensus of $7 billion, primarily due to higher sales in HIV and Veklury&nbsp;(remdesivir), Oncology and Liver Disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434127/gilead-sciencesmercks-investigational-once-weekly-hiv-combo-therapy-shows-sustained-virus-suppres" rel="noreferrer noopener">Gilead Sciences/Merck&#8217;s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks</a>
HIV&nbsp;product sales increased 9% to $5.1 billion, with Biktarvy sales increased 13% to $3.5 billion. Descovy&nbsp;sales jumped 15% to $586 million.
The&nbsp;Liver Disease&nbsp;portfolio sales increased 4% to $733 million. Veklury&nbsp;sales increased 9% to $692 million.
&#8220;Gilead&#8217;s third-quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy,&#8221; said Daniel O&#8217;Day, Chairman and CEO.
Guidance: Gilead Sciences raised its fiscal year 2024 adjusted EPS guidance from $3.60 &#8211; $3.90 to $4.25 &#8211; $4.45 compared to the consensus of $3.81.
The company expects 2024 product sales of $27.8 billion &#8211; $28.1 billion compared to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">prior guidance of</a> $27.1 billion &#8211; $27.5 billion.
Analysts&#8217; reaction:
<ul>
<li>Piper Sandler maintains Gilead Sciences with an Overweight, raising the price <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $95 to $105</a>.</li>
<li>Barclays reaffirms Gilead with an Equal-Weight rating while boosting the price target from $84 to $95.</li>
<li>Wells Fargo maintains Gilead with an Overweight rating, raising the price target from $100 to $105.</li>
<li>Cantor Fitzgerald reiterates Gilead with a Neutral rating, increasing the price target from $70 to $80.</li>
<li>Goldman Sachs maintains Gilead&#8217;s Neutral rating, lifting the price target from $74 to $84.</li>
<li>RBC Capital maintains Gilead&#8217;s Sector Perform rating and boosts the price target from $75 to $81.</li>
<li>JP Morgan maintains Gilead with an Overweight rating, raising the price target from $100 to $105.</li>
<li>Baird maintains Gilead&#8217;s Neutral rating, increasing the price target from $80 to $95.</li>
</ul>
Price Action: GILD stock is up 5.94% at $97.14 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales</a></li>
</ul>

Analyst Color

Biotech

Earnings

Equities

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

After Wednesday&#8217;s &#8220;everything rally&#8221; spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting.
The Fed is widely expected to cut interest rates by 25 basis points, bringing them to a range of 4.5%-4.75%, following a previous 50-basis-point cut in September.
Yet, all eyes are on Fed Chair Jerome Powell&#8217;s comments at 2:30 p.m. ET regarding the potential for future rate hikes and his views on inflation risks. Concerns from the market center on the possibility of a policy U-turn driven by higher fiscal deficits and price pressures from trade tariffs under a Trump administration.
Tech stocks led gains, with the Nasdaq 100 extending its record-breaking levels, surpassing 21,000 points and eyeing a third consecutive positive session. The S&amp;P 500 and Dow Jones posted more modest gains, while the Russell 2000 paused after Wednesday&#8217;s 5.8% leap.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remained a top performer among mega-cap stocks, bolstered by expectations of Elon Musk&#8216;s influence in the upcoming administration.
Treasury yields reversed a substantial portion of Wednesday's post-election increase, while the U.S. dollar dipped by 0.7%.
Metal commodities rebounded after Wednesday&#8217;s sharp losses, with gold rising 1.3%, silver up 2% and copper rallying over 4%.
Oil prices strengthened by 1%, with West Texas Intermediate trading around $72 per barrel.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 0.8%, reaching $76,000 to extend its record highs, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) outperformed with a gain of over 4%.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,050.78</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,968.27</td>
<td>0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,748.20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.10</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.7% to $594.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;stalled at $437.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.3% to $512.38.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.3% to $236.67.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, rising 1.3%. The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Some relevant reactions to earnings reports are:
<ul>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), up 0.1%, </li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), up 6.2%, </li>
<li>MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), down 16%, </li>
<li>APPLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), up 43%, </li>
<li>McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), up 11%, </li>
<li>Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), up 6.3%, </li>
<li>Transdigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>), down 4.4%</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
This image was created using artificial intelligence.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

$ETH

SPDR Dow Jones Industrial Average ETF Trust

MELI

QCOM

TSLA

TTWO

XLRE

Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?

BMO Capital analyst Evan Seigerman maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $94 to $102.

BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $102

Baird analyst Brian Skorney maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $80 to $95.

Baird Maintains Neutral on Gilead Sciences, Raises Price Target to $95

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $100 to $105.

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $105

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and raises the price target from $75 to $81.

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $81

Goldman Sachs analyst Salveen Richter maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $74 to $84.

Goldman Sachs Maintains Neutral on Gilead Sciences, Raises Price Target to $84

Cantor Fitzgerald analyst Olivia Brayer maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $70 to $80.

Cantor Fitzgerald Maintains Neutral on Gilead Sciences, Raises Price Target to $80

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $100 to $105.

Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $105

Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Equal-Weight and raises the price target from $84 to $95.

Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $95

WIIM

Gilead Sciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance.

Piper Sandler analyst Joseph Catanzaro maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $95 to $105.

Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $105

– Full Results From PURPOSE 2 Study Exploring Lenacapavir as a Potential Twice-Yearly HIV Prevention Option Among a Broad and Geographically Diverse Range of Cisgender Men and Gender-Diverse People –
– Four-Year Outcomes From Real-World BICSTaR Study Further Demonstrate the Consistent Efficacy and Safety Profile of Biktarvy, Providing Insights for HIV Clinical Care –
– Late-Breaking Oral Presentation From Phase 2 Study Evaluating an Investigational Once-Weekly Oral Combination Treatment Regimen of Islatravir/Lenacapavir –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fhivglasgow.org%2F&amp;esheet=54147944&amp;newsitemid=20241107836956&amp;lan=en-US&amp;anchor=HIV+Glasgow+2024&amp;index=1&amp;md5=c8ec2f40b1e76ef7065a46ac0f3d36e9">HIV Glasgow 2024</a>), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic.

Gilead Sciences Announces Late-Breaking Clinical Data And Real-World Evidence To Be Presented At HIV Glasgow As Co Extends Leadership Efforts Toward Ending The Epidemic

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Gilead Sciences

Gilead Sciences Raises FY24 Adj EPS Outlook From $3.60 - $3.90 To $4.25 - $4.45, Est $3.81

Gilead Sciences Raises FY24 Product sales Guidance From $27.10B - $27.50B To $27.80B - $28.10B

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $1.55 by 30.32 percent. This is a 11.79 percent decrease over earnings of $2.29 per share from the same period last year. The company reported quarterly sales of $7.54 billion which beat the analyst consensus estimate of $7.00 billion by 7.73 percent. This is a 7.01 percent increase over sales of $7.05 billion the same period last year.

Earnings Beats

Gilead Sciences Q3 2024 Adj EPS $2.02 Beats $1.55 Estimate, Sales $7.54B Beat $7.00B Estimate

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.95% on an annualized basis producing an average annual return of 12.29%. Currently, Gilead Sciences has a market capitalization of $113.57 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,878.72 today based on a price of $91.22 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730917830_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price tar...

Gilead Sciences: Strong Financial Performance and Promising Outlook Underpin Buy Rating

In a report released today, Carter Gould from Barclays maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of...

Barclays Remains a Hold on Gilead Sciences (GILD)

Gilead Sciences declares $0.77 dividend

Barclays analyst Carter Gould raised the firm's price target on Gilead (GILD) to $95 from $84 and keeps an Equal Weight rating on the shares. The c...

Gilead price target raised to $95 from $84 at Barclays

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. C...

Gilead Sciences: Strong Financial Performance and Growth Potential Drive Buy Rating

JPMorgan raised the firm's price target on Gilead (GILD) to $105 from $100 and keeps an Overweight rating on the shares. The company reported a sal...

Gilead price target raised to $105 from $100 at JPMorgan

Mohit Bansal, an analyst from Wells Fargo, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target was r...

Buy Recommendation for Gilead Sciences: Strong HIV Business Performance and Strategic Initiatives Drive Optimism

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, taking p...

Gilead to present HIV research findings at conference

Notable gainers among liquid option names this morning include EPAM Systems (EPAM) $233.69 +31.00, Warner Bros. Discovery (WBD) $9.52 +1.14, Viatri...

Early notable gainers among liquid option names on November 7th

Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time.

3 Healthcare Stocks For Long-Term Growth And Dividends

AMGN

EPAM

VTRS

Press Releases

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

Comments

Gilead Sciences

空売り

Gilead Sciences (NASDAQ:GILD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル